Document is current
Any future updates will be listed below
-
Authors
Strand, Siri H.
Houlahan, Kathleen E.
Branch, Vernal
Lynch, Thomas
Rivero-Guitiérrez, Belén
Harmon, Bryan
Couch, Fergus
Gallagher, Kristalyn
Kilgore, Mark
Wei, Shi
DeMichele, Angela
King, Tari
McAuliffe, Priscilla
Curtis, Christina
Owzar, Kouros
Marks, Jeffrey R.
Colditz, Graham A.
Hwang, E. Shelley
West, Robert B.
-
Funding
Funding for this research was provided by:
National Cancer Institute (CA-17-035, CA-17-035, CA-17-035)
Department of Defense (BC132057)
Breast Cancer Research Foundation (PPI-18-006)
- License Information
-
More Information
Article History
Received: 16 March 2024
Accepted: 21 August 2024
First Online: 2 September 2024
Declarations
:
: The RAHBT study was approved by the Washington University in St. Louis Institutional Review Board (IRB ID #: 201707090). The TBCRC 038 study was approved by the Duke Health Institutional Review Board (Protocol ID: Pro00068646) as well as the IRB at each participating institution.
: Not applicable.
: CC serves on the Scientific Advisory Board and/or as consultant for Bristol Myers Squibb, Deepcell, Genentech, NanoString, Ravel, Viosera, and holds equity in Deepcell, Illumina/Grail, and Ravel. RBW has consulted for IonPath Inc.
